ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $9.00 price target on the stock.
Separately, Piper Sandler reissued an “overweight” rating and issued a $10.00 price objective (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.
Read Our Latest Research Report on ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Price Performance
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) last issued its quarterly earnings data on Friday, April 12th. The company reported ($0.78) earnings per share for the quarter. On average, equities research analysts expect that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.
ASLAN Pharmaceuticals Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
Read More
- Five stocks we like better than ASLAN Pharmaceuticals
- The “How” and “Why” of Investing in 5G Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- What is the Hang Seng index?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Where Do I Find 52-Week Highs and Lows?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.